Clinical trials: PCI
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study
The purpose of this study is to evaluate the efficacy of ARALAST NP A1PI augmentation therapy 120 milligrams per kilogram (mg/kg) body weight (BW)/week compared with an external placebo comparator on the loss of emphysematous…
- Trial name
- NCT04440488
- Testing
- ARALAST NP
- Sponsor
- Shire
Coronary Artery Stenosis
Kidney Damage in Patients With Normal eGFR
This is a pilot study, randomized, double-blind, parallel group comparison of two iodinated contrast agents used during percutaneous coronary intervention (PCI). All patients enrolled must have normal eGFR.
- Trial name
- NCT01137786
- Testing
- Non ionic contrast media comparator
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Bracco Diagnostics, Inc
Stable Coronary Artery Disease, Percutaneous Coronary Intervention
Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy
This study is conducted to assess the safety of CMX-2043 solution for intravenous (IV) injection, and to evaluate efficacy on the basis of the changes seen in the cardiac biomarkers and continuous electrocardiography (ECG)…
- Trial name
- SUPPORT-1 (NCT00984802)
- Testing
- CMX-2043
- Where
- 5 sites in United States, India
- Volunteers
- 142 people
- Sponsor
- Ischemix, LLC
Coronary Artery Disease
PMCF Study for Cardiology Access Procedures
This Post-market clinical follow-up (PMCF) study is designed as retrospective, multi-center study to collect real-life data. A multi-center design is used to ensure a representative sample of the physicians who have performed the…
- Trial name
- NCT05543096
- Testing
- Adroit Guiding Catheter, Cordis Transradial Access Devices, Cordis Diagnostic Catheters, Cordis Guidewires
- Where
- 8 sites in Austria, Belgium
- Volunteers
- 200 people
- Sponsor
- Cordis US Corp.
Cystic Fibrosis
Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis
This was a randomized, double-blind, placebo-controlled, dose escalation study to assess the safety and tolerability of 100 mg and 200 mg of inhaled Alpha-1 HC administered once a day for three weeks in subjects aged 18 years and…
- Trial name
- NCT01684410
- Testing
- Alpha-1 HC 100 mg, Alpha-1 HC 200 mg
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Grifols Therapeutics LLC
Coronary Artery Disease
FAME II-10-year Follow-Up
The FAME-II trial was a prospective, multicenter, multinational, multi-continental, randomized clinical trial with an 'all comers' design.
- Trial name
- FAME2-10yFU (NCT06159231)
- Where
- 16 sites in United States, Belgium and 9 more
- Volunteers
- 888 people
- Sponsor
- CoreAalst BV
ST Elevation Myocardial Infarction
A Prospective Evaluation of Clinical Impact of Physiology Versus Optical Coherence Tomography Guided PCI in STEMI Patients Without Undergoing Primary PCI
This study of physiologically functional FFR in STEMI patients without direct PCI treatment will provide unique data on plaque progression and risk factors.
- Trial name
- NCT04996277
- Testing
- angiography, Thrombus suction, Fibrinolytic therapy
- Volunteers
- 300 people
- Sponsor
- CCRF Inc., Beijing, China
Myocardial Infarction
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood…
- Trial name
- NCT00046228
- Where
- 227 sites in United States, Argentina and 17 more
- Volunteers
- 2,461 people
- Sponsor
- Centocor, Inc.
Diabetes Mellitus
BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY
The main objective of this study is to assess the safety, efficacy and dose response of LABR-312 administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent in reducing restenosis…
- Trial name
- BLADE (NCT02645799)
- Testing
- LABR-312
- Where
- Israel
- Volunteers
- 270 people
- Sponsor
- BIOrest Ltd.
Coronary Artery Lesions
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary…
- Trial name
- NCT03218787
- Testing
- XIENCE, DAPT
- Where
- 101 sites in United States
- Volunteers
- 2,047 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Observational Registry Study: FIREHAWK DES for Treating Coronary Artery Disease (CAD)
The study aims to further assess the safety, efficacy and the performance of its delivery system of FIREHAWK rapamycin-eluting stent up to five years.
- Trial name
- NCT01412164
- Testing
- FIREHAWK biodegradable polymer rapamycin-eluting stent
- Where
- China
- Volunteers
- 730 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
STEMI - ST Elevation Myocardial Infarction, CAD
CorPath GRX STEMI Study
This study will evaluate the performance of the CorPath GRX System in Robotic Primary PCI (RPPCI) in the treatment of ST-elevated myocardial infarction (STEMI).
- Trial name
- TREAT GRX (NCT04459299)
- Testing
- Robotic-PCI (CorPath GRX System)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
Coronary Disease
Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety
This trial aims to demonstrate the non-inferiority of the CI-CMS-005 Coronary Stent System to the study device as well as to the TAXUS™ Express2™ Drug-Eluting Coronary Stent System in in-segment late lumen loss at 9 months after…
- Trial name
- NCT00415961
- Testing
- CoStar Paclitaxel Drug-Eluting Coronary Stent System
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Conor Medsystems
High Risk PCI, Coronary Arterial Disease (CAD)
Prospective Evaluation for Receiving SynFlow 3.0 Interventional Circulatory Support in High-risk PCI: A Randomized Controlled Trial
This study is conducted to compare the effectiveness of a new percutaneous mechanical circulatory support device called SynFlow 3.0 with VA-ECMO in high-risk percutaneous coronary intervetnion(PCI) patients.
- Trial name
- PERSIST Ⅲ (NCT06853470)
- Testing
- VA-ECMO circulatory support, SynFlow 3.0 circulatory support, percutaneous coronary intervention
- Where
- China
- Volunteers
- 222 people
- Sponsor
- ForQaly Medical (Shanghai) Co., Ltd
Stable Angina Pectoris, Atherosclerosis
Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris
Molsidomine used as an add-on treatment on standard care therapy should be superior to placebo used also as an add-on treatment on standard care therapy on improving the endothelial function (endothelium score measured by…
- Trial name
- MEDCOR (NCT01363661)
- Testing
- Coruno
- Where
- Belgium
- Volunteers
- 165 people
- Sponsor
- Therabel Pharma SA/NV
Complex Coronary Lesions
Intravascular Ultrasound Guidance for Complex High-risk Indicated Procedures
The IVUS CHIP trial is a post-marketing strategy study in which patients with complex coronary lesions, undergoing percutaneous coronary intervention (PCI), are treated either with intravascular ultrasound (IVUS) guided PCI or…
- Trial name
- IVUS-CHIP (NCT04854070)
- Testing
- IVUS, Angio
- Where
- 37 sites in Belgium, France and 5 more
- Volunteers
- 2,020 people
- Sponsor
- ECRI bv
Acute Coronary Syndrome (ACS)
Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI)
This Phase IV, multicenter trial is designed to assess the efficacy of prasugrel in preventing the formation of blood clots in Taiwanese patients with ACS who have been treated with PCI.
- Trial name
- NCT03672097
- Testing
- Prasugrel
- Where
- 10 sites in Taiwan
- Volunteers
- 204 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI)
Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients
This is a multicenter, randomized and open-label Phase II study to compare the safety, tolerability and biological effectiveness of ALX-0081 versus the GPIIb/IIIa inhibitor ReoPro® in high risk PCI patients.
- Conditions
- Unstable Angina, Non ST Segment Elevation Myocardial Infarction (NSTEMI), Stable Angina (Associated With High Risk PCI)
- Trial name
- NCT01020383
- Testing
- ALX-0081, ReoPro®
- Where
- 39 sites in Austria, Belgium and 5 more
- Volunteers
- 364 people
- Sponsor
- Ablynx, a Sanofi company
Acute Myocardial Infarction
Bivalirudin in Acute Myocardial Infarction
The purpose of the study is to evaluate the efficacy and safety of bivalirudin in AMI patients with DES. This is a prospective, randomized, single-blind, active drug controlled multicenter clinical research and the study would…
- Trial name
- NCT02897037
- Testing
- Bivalirudin, heparin
- Where
- China
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Acute Myocardial Infarction, STEMI
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
A multi-center randomized post-approval evaluation of delivery of intracoronary hyperoxemic supersaturated Oxygen therapy for 60 minutes in anterior AMI patients with successful reperfusion (via PCI) within 6 hours after onset of…
- Trial name
- NCT04743245
- Testing
- TherOx DownStream System, PCI
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- TherOx